Incyte | INCY - Cash And Equivalent

Stock Price
97.80
Daily Change
2.08 2.17%
Monthly
8.27%
Yearly
61.84%
Q2 Forecast
92.62

Incyte reported $4.02B in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 819.69M 27.33M Dec/2025
Agenus USD 3.46M 6.08M Sep/2025
Agios Pharmaceuticals USD 89.13M 3.58M Dec/2025
Alnylam Pharmaceuticals USD 1.66B 167M Dec/2025
Amgen USD 9.13B 316M Dec/2025
BioCryst Pharmaceuticals USD 335.91M 251.83M Dec/2025
Biogen USD 3.01B 854.3M Dec/2025
BioMarin Pharmaceutical USD 1.31B 61.57M Dec/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Eli Lilly USD 7.27B 2.52B Dec/2025
Exelixis USD 482.49M 106.19M Dec/2025
Gilead Sciences USD 7.56B 234M Dec/2025
Incyte USD 4.02B 435.22M Mar/2026
Ionis Pharmaceuticals USD 2.68B 437M Dec/2025
MacroGenics USD 57.22M 22.91M Dec/2025
Merck USD 18.17B 10.16B Sep/2025
Moderna USD 2.6B 1.46B Dec/2025
Nektar Therapeutics USD 15.12M 25.92M Dec/2025
Neurocrine Biosciences USD 713M 372.8M Dec/2025
Novartis USD 11.44B 1.88B Dec/2025
Novartis USD 9.56B 2.9B Sep/2025
Pfizer USD 1.34B 295M Sep/2025
PTC Therapeutics USD 984.65M 312.03M Dec/2025
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Sarepta Therapeutics USD 801.28M 188.2M Dec/2025
Ultragenyx Pharmaceutical USD 202.51M 36.4M Sep/2025
Vertex Pharmaceuticals USD 6.61B 321.1M Dec/2025